Ç×°£Áú¾à ½ÃÀå ¿¹Ãø(-2030³â) : ¹ßÀÛ À¯Çü, Åõ¿© °æ·Î, ¾à¹° ¼¼´ë, À¯Åë ä³Î ¹× Áö¿ªº° ¼¼°è ½ÃÀå ºÐ¼®
Antiepileptic Drugs Market Forecasts to 2030 - Global Analysis By Types of Seizures, Route of Administration, Drug Generation, Distribution Channel and By Geography
»óǰÄÚµå : 1403455
¸®¼­Ä¡»ç : Stratistics Market Research Consulting
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,150 £Ü 6,004,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (2-5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,350 £Ü 9,187,000
PDF & Excel (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,851,000
PDF & Excel (Global Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Stratistics MRC¿¡ µû¸£¸é ¼¼°è Ç×°£ÁúÁ¦ ½ÃÀåÀº 2023³â 185¾ï ´Þ·¯, 2030³â 287¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 6.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°£ÁúÀº ³úÀÇ ºñÁ¤»óÀûÀÎ Àü±âÀû Ȱµ¿À¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹Ýº¹ÀûÀÌ°í ¿¹ÃøÇÒ ¼ö ¾ø´Â ¹ßÀÛÀÌ Æ¯Â¡ÀÎ ½Å°æ ÁúȯÀÔ´Ï´Ù. Ç×°£Áú¾àÀº ³úÀÇ Àü±âÀû Ȱµ¿À» Á¶ÀýÇÏ¿© ¹ßÀÛÀ¸·Î À̾îÁö´Â ºñÁ¤»óÀûÀÎ Ãæµ¿À» ¿¹¹æÇϰųª °¨¼Ò½ÃŰ´Â ÀÛ¿ëÀ» Çϸç, AED´Â ¼¼Æ÷¸·À» ¾ÈÁ¤È­½Ã۰í, GABA¿Í °°Àº ¾ïÁ¦¼º ½Å°æÀü´Þ¹°ÁúÀ» °­È­Çϸç, ³ªÆ®·ý ä³ÎÀ» Â÷´ÜÇϰí, ±Û·çŸ¸ÞÀÌÆ®ÀÇ ÈïºÐ¼ºÀ» ³·Ã߰ųª, Ä®½· ä³ÎÀ» Á¶ÀýÇÕ´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)ÀÇ 2023³â 2¿ù 9ÀÏ ¹ßÇ¥¿¡ µû¸£¸é, Àü ¼¼°èÀûÀ¸·Î ¸Å³â 500¸¸ ¸íÀÌ °£Áú Áø´ÜÀ» ¹Þ°í ÀÖ½À´Ï´Ù. °í¼Òµæ ±¹°¡¿¡¼­´Â 10¸¸ ¸í Áß 49¸íÀÌ °£ÁúÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

ÀǾàǰ °³¹ßÀÇ Áøº¸

Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß ³ë·ÂÀ¸·Î »õ·Î¿î Á¦Çü, »õ·Î¿î ÀÛ¿ë±âÀü, °³¼±µÈ ¾à¹°Àü´Þ½Ã½ºÅÛÀÌ ¹ß°ßµÇ¸é¼­ Ç׳úÀüÁõ Ä¡·áÀÇ »óȲÀÌ º¯È­Çϰí ÀÖ½À´Ï´Ù. Â÷¼¼´ë Ç×°£Áú¾àÀÇ µµÀÔÀº ºÎÀÛ¿ë°ú ºÒ¿ÏÀüÇÑ ¹ßÀÛ Á¶Àý°ú °°Àº ±âÁ¸ Ä¡·á¹ýÀÇ ÇѰ踦 ±Øº¹ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼­¹æÇü Á¦Á¦¸¦ Æ÷ÇÔÇÑ Ã·´Ü Á¦Á¦µéÀº Åõ¿© ¹æ½ÄÀ» °³¼±ÇÏ¿© ȯÀÚÀÇ º¹¾à ¼øÀÀµµ¿Í Àü¹ÝÀûÀÎ Ä¡·á È¿°ú¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀǾàǰ °³¹ßÀÇ ¹ßÀüÀº ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎÀÛ¿ë

ÀϹÝÀûÀÎ ºÎÀÛ¿ëÀ¸·Î´Â ¾îÁö·³Áõ, ÇÇ·Î, ÀÎÁö Àå¾Ö, ±âºÐ º¯È­ µîÀÌ ÀÖÀ¸¸ç, À̴ ȯÀÚÀÇ »îÀÇ Áú¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ¹®Á¦´Â ¹ßÀÛ ¾ïÁ¦¶ó´Â Ä¡·á È¿°ú¿Í ÀÌ·¯ÇÑ ºÎÀÛ¿ëÀÇ ³»¾à¼º »çÀÌÀÇ ±ÕÇüÀ» ¸ÂÃß´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ºÎÀÛ¿ëÀº ȯÀÚÀÇ ºÒ¸¸Á·, ¼øÀÀµµ ÀúÇÏ, Ä¡·á Áß´ÜÀ¸·Î À̾îÁ® Ç×°£Áú¾à Ä¡·áÀÇ È¿°ú¸¦ ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÎÀÛ¿ëÀº ½ÃÀå È®´ë¿¡ Å« °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

°£Áú À¯º´·ü Áõ°¡

°£ÁúÀº Àç¹ß¼º ¹ßÀÛÀÌ Æ¯Â¡ÀÎ ½Å°æÁúȯÀ¸·Î, Àü ¼¼°èÀûÀ¸·Î ¸¹Àº ¼öÀÇ È¯ÀÚ°¡ ¾Î°í ÀÖ½À´Ï´Ù. °£Áú À¯º´·ü Áõ°¡´Â ¸î °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ù°, Áø´Ü ±â¼úÀÇ ¹ßÀü°ú °£Áú¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ °£Áú ¹ß°ßÀ²ÀÌ ³ô¾ÆÁ³½À´Ï´Ù. ÀÇÇÐ Áö½Ä°ú ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÇ·á Àü¹®°¡µéÀÌ °£ÁúÀ» Á¤È®ÇÏ°Ô Áø´ÜÇÏ°í ºÐ·ùÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÀÎ½Ä °³¼± Ä·ÆäÀΰú ±³À° ÇÁ·Î±×·¥À» ÅëÇØ °£Áú Áõ»ó°ú Á¶±â Áø´ÜÀÇ Á߿伺¿¡ ´ëÇÑ Áö½ÄÀÌ ³Î¸® ÆÛÁ® ÀÇ·á ±â°üÀ» ã´Â »ç¶÷µéÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

»çȸÀû ³«ÀÎ

³úÀüÁõÀ̶ó´Â ½Å°æÁúȯ¿¡ ´ëÇÑ ÀÌÇØ´Â Á¡Á¡ ´õ ¹ßÀüÇϰí ÀÖÁö¸¸, °£Áú¿¡ ´ëÇÑ »çȸÀû ¿ÀÇØ´Â ¿©ÀüÈ÷ Á¸ÀçÇϸç ÀûÀýÇÑ Ä¡·á¸¦ ¹Þ´Â °ÍÀ» ÁÖÀúÇÏ°Ô ¸¸µå´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. °£Áú¿¡ ´ëÇÑ ³«ÀÎÀº Áø´Ü Áö¿¬°ú Ä¡·á Áö¿¬À¸·Î À̾îÁú ¼ö ÀÖÀ¸¸ç, »çȸÀû ÆÇ´Ü°ú Â÷º°À» µÎ·Á¿öÇØ º´À» °ø°³Çϰųª ÀÇ·áÀû µµ¿òÀ» ¿äûÇÏ´Â °ÍÀ» ±âÇÇÇÏ´Â »ç¶÷µéµµ ÀÖ½À´Ï´Ù. °£Áú¿¡ ´ëÇØ °ø°³ÀûÀ¸·Î À̾߱âÇÏ´Â °ÍÀ» ²¨¸®´Â °ÍÀº À߸øµÈ Á¤º¸¸¦ ¾ÇÈ­½Ã۰í, ȯÀÚ°¡ Ç×°£Áú¾àÀÇ ÇÊ¿äÇϰí È¿À²ÀûÀÎ Ä¡·á¸¦ ¹Þ´Â °ÍÀ» ¹æÇØÇϸç, ȯÀÚ ±³À°À» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ½ÃÀå ¼ö¿ä¸¦ ÀúÇØÇÏ´Â ¿äÀÎÀÔ´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

Äڷγª19 ÆÒµ¥¹ÍÀº Ç×°£Áú¾à(AED) ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Àü¿°º´Àº ȸº¹·Â ÀÖ´Â ÀÇ·á ½Ã½ºÅÛÀ» È®º¸ÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù´Â °ÍÀ» °­Á¶Çß½À´Ï´Ù. ¿ø°Ý ÀÇ·á ¼Ö·ç¼Ç°ú ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÌ °¢±¤À» ¹Þ¾Æ °£Áú °ü¸®¿¡ ´ë¾ÈÀ» Á¦°øÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, Äڷγª19ÀÇ ½Å°æÇÐÀû ÇÕº´Áõ¿¡ ´ëÀÀÇϱâ À§ÇÑ ¿¬±¸°³¹ß¿¡ ÁýÁßÇÔÀ¸·Î½á °£Áú ¹× °ü·Ã Áúȯ¿¡ ´ëÇÑ ÀÌÇØµµ¸¦ ³ôÀÌ´Â µ¥ °£Á¢ÀûÀ¸·Î ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °ø±Þ¸ÁÀÇ È¥¶õ°ú °æÁ¦ÀÇ ºÒÈ®½Ç¼ºÀÌ AEDÀÇ »ý»ê°ú À¯Åë¿¡ ¿µÇâÀ» ¹ÌÃÄ ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È 3¼¼´ë ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

3¼¼´ë ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶óÄÚ»ç¹Ìµå, ¿¡½º¸®Ä®¹ÙÁ¦ÇÉ, Æä¶õÆÇ³Ú°ú °°Àº ÀÌ ¾à¹°µéÀº °£Áú ¹ßÀÛ °ü¸®¿¡ ÀÖ¾î ´õ ³ôÀº ƯÀ̼º°ú È¿´ÉÀ» º¸À̰í ÀÖ½À´Ï´Ù. 3¼¼´ë AED´Â ´ëºÎºÐ »õ·Î¿î ºÐÀÚ °æ·Î¸¦ Ç¥ÀûÀ¸·Î »ï±â ¶§¹®¿¡ ÀÛ¿ë ½ºÆåÆ®·³ÀÌ ³Ð°í ½Å°æ¼¼Æ÷ Ȱµ¿À» Á¶ÀýÇÏ´Â ¼±ÅüºÀÌ ³ô½À´Ï´Ù. 3¼¼´ë AEDÀÇ °¡Àå Å« Ư¡ Áß Çϳª´Â ºÎÀÛ¿ë°ú ¾à¹° »óÈ£ ÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â µ¥ ÁßÁ¡À» µÎ¾î Àü¹ÝÀûÀÎ ³»¾à¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù´Â Á¡ÀÔ´Ï´Ù. À̴ ȯÀÚÀÇ Ä¡·á ¿ä¹ý ¼øÀÀµµ¸¦ ³ôÀÌ´Â µ¥ ƯÈ÷ Áß¿äÇÕ´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â °æ±¸ ºÎ¹®

°æ±¸Á¦ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °æ±¸ Åõ¿©´Â Á¤Á¦, ĸ½¶, ¾×»ó ÇüÅ·ΠÇ×°£Áú¾à¸¦ ¼·ÃëÇϱ⠶§¹®¿¡ ¼ÒÈ­°üÀ» ÅëÇÑ ¾à¹° Èí¼ö°¡ Æí¸®Çϰí È¿À²ÀûÀÔ´Ï´Ù. °æ±¸ Åõ¿©´Â ¾à¹° ó¹æ¿¡ À¯¿¬¼ºÀ» °¡Á®´ÙÁÖ¸ç, ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ¼­¼­È÷ ¾à¹°À» ¹æÃâÇÏ´Â ¼­¹æÇü Á¦Á¦ÀÇ °³¹ßÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Æ¯Â¡Àº Ç÷Áß ¾à¹° ³óµµ¸¦ ÀÏÁ¤ÇÏ°Ô À¯ÁöÇÏ¿© Ä¡·á È¿°ú¸¦ ÃÖÀûÈ­ÇÏ°í ¹ßÀÛÀ» À¯¹ßÇÒ ¼ö ÀÖ´Â º¯µ¿À» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

°¡Àå ³ôÀº Á¡À¯À²À» º¸ÀÌ´Â Áö¿ª

ºÏ¹Ì´Â źźÇÑ ÀÇ·á ÀÎÇÁ¶ó, ÷´Ü ÀÇÇÐ ¿¬±¸, °£Áú °ü·Ã ÁúȯÀÇ ³ôÀº À¯º´·ü·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ Áö¿ªÀÇ Á¦¾à »ê¾÷Àº Àß È®¸³µÇ¾î ÀÖÀ¸¸ç, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ·Î Ç×°£Áú Ä¡·áÀÇ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç¿Í ÷´Ü ±â¼úÀÇ Ã¤ÅÃÀº ÀÌ Áö¿ªÀÇ Ä¡·á ¿É¼Ç ¹ßÀüÀÇ ¸®´õ½Ê¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª :

¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÎ½Ä °³¼±, ÀÇ·á ÀÎÇÁ¶ó °³¼±, °£Áú °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ¼öÀͼº ³ôÀº ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´õ ³ªÀº Áø´ÜÀ¸·ÎÀÇ Àüȯ°ú ȯÀÚ ±³À° Áõ°¡´Â ÀÌ Áö¿ªÀÇ Ç×°£ÁúÁ¦ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´Ù¾çÇÑ Àα¸ ±¸¼º°ú dzºÎÇÑ È¯ÀÚ ±â¹ÝÀ» °¡Áø ÀÌ Áö¿ªÀº Ç×°£Áú¾à °³¹ß ¹× ÆÇ¸Å¿¡ Á¾»çÇÏ´Â Á¦¾àȸ»çµé¿¡°Ô Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¹«·á ¸ÂÃãÇü ¼­ºñ½º :

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÇü ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø, CAGR(Âü°í: Ÿ´ç¼º È®Àο¡ µû¶ó ´Ù¸§)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

Á¦4Àå PorterÀÇ Five Forces ºÐ¼®

Á¦5Àå ¼¼°èÀÇ Ç×°£Áú¾à ½ÃÀå : ¹ßÀÛ À¯Çüº°

Á¦6Àå ¼¼°èÀÇ Ç×°£Áú¾à ½ÃÀå : Åõ¿© °æ·Îº°

Á¦7Àå ¼¼°èÀÇ Ç×°£Áú¾à ½ÃÀå : ½Å¾à ¼¼´ëº°

Á¦8Àå ¼¼°èÀÇ Ç×°£Áú¾à ½ÃÀå : À¯Åë ä³Îº°

Á¦9Àå ¼¼°èÀÇ Ç×°£Áú¾à ½ÃÀå : Áö¿ªº°

Á¦10Àå ÁÖ¿ä ¹ßÀü

Á¦11Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to Stratistics MRC, the Global Antiepileptic Drugs Market is accounted for $18.5 billion in 2023 and is expected to reach $28.7 billion by 2030 growing at a CAGR of 6.5% during the forecast period. Epilepsy is a neurological disorder characterized by recurrent and unpredictable seizures, which are caused by abnormal electrical activity in the brain. Antiepileptic drugs work by modulating the electrical activity in the brain, preventing or reducing abnormal impulses that lead to seizures. AEDs stabilize cell membranes, enhance inhibitory neurotransmitters like GABA, block sodium channels, reduce glutamate excitability, or modulate calcium channels.

According to World Health Organization (WHO) on February 09, 2023, 5 million people are diagnosed globally with epilepsy every year. Epilepsy is estimated to affect 49 persons out of every 100,000 in high-income countries every year.

Market Dynamics:

Driver:

Advancements in drug development

Continuous research and development efforts have led to the discovery of new formulations, novel mechanisms of action, and improved drug delivery systems, revolutionizing the landscape of antiepileptic treatments. The introduction of next-generation antiepileptic drugs has aimed to address limitations associated with traditional therapies, such as adverse side effects and incomplete seizure control. Additionally, advanced formulations, including extended-release versions, offer improved dosing regimens, enhancing patient adherence and overall treatment efficacy. These advancements in drug development propel market demand.

Restraint:

Side effects

Common side effects include dizziness, fatigue, cognitive impairment, and mood alterations, which can significantly impact patients' quality of life. The challenge lies in balancing the therapeutic benefits of seizure control with the tolerability of these side effects. Moreover, the occurrence of adverse reactions may lead to patient dissatisfaction, non-compliance, or discontinuation of treatment, impeding the effectiveness of antiepileptic therapy. These side effects pose a significant restraint, hampering market expansion.

Opportunity:

Rising prevalence of epilepsy

Epilepsy is a neurological disorder characterized by recurrent seizures, and it affects a substantial number of individuals worldwide. The rising prevalence of epilepsy can be attributed to several factors. Firstly, improved diagnostic techniques and increased awareness of epilepsy have contributed to a higher detection rate. As medical knowledge and technological advancements have improved, healthcare professionals are better equipped to diagnose and classify epilepsy accurately. Additionally, awareness campaigns and educational programs have helped spread knowledge about epilepsy symptoms and the importance of early diagnosis, leading to more individuals seeking medical attention.

Threat:

Social stigma

Despite advancements in understanding the neurological condition, societal misconceptions persist, contributing to reluctance among individuals to seek appropriate treatment. The stigma surrounding epilepsy may lead to under diagnosis and under treatment, as some individuals may avoid disclosing their condition or seeking medical help due to fear of social judgment or discrimination. This unwillingness to discuss epilepsy in public can worsen misinformation, prevent patients from receiving the necessary and efficient treatment that antiepileptic medications provide, and impede patient education. These factors impede market demand.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the Antiepileptic Drugs (AEDs) market. Pandemic has underscored the importance of ensuring a resilient healthcare system. Telehealth solutions and remote patient monitoring have gained prominence, providing alternative avenues for epilepsy management. Additionally, the focus on research and development to address neurological complications of COVID-19 has indirectly contributed to advancements in understanding epilepsy and related disorders. Moreover, supply chain disruptions and economic uncertainties have impacted the production and distribution of AEDs, affecting market dynamics.

The third generation segment is expected to be the largest during the forecast period

The third generation segment is estimated to hold the largest share. These drugs, such as lacosamide, eslicarbazepine, and perampanel, exhibit enhanced specificity and efficacy in managing epileptic seizures. Third-generation AEDs often target novel molecular pathways, providing a broader spectrum of action and greater selectivity in modulating neuronal activity. One key feature of third-generation AEDs is their focus on minimizing side effects and drug interactions, thus improving overall tolerability. This is particularly important in enhancing patient adherence to treatment regimens.

The Oral segment is expected to have the highest CAGR during the forecast period

The Oral segment is anticipated to have lucrative growth during the forecast period. Oral administration involves the ingestion of antiepileptic drugs in the form of tablets, capsules, or liquids, allowing for convenient and efficient drug absorption through the gastrointestinal tract. The oral route provides flexibility in drug formulation, enabling the development of extended-release formulations that release the medication gradually over time. This feature helps maintain consistent drug levels in the bloodstream, optimizing therapeutic efficacy and minimizing fluctuations that could trigger seizures.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to robust healthcare infrastructure, advanced medical research, and a high prevalence of epilepsy-related disorders. The region's well-established pharmaceutical industry, coupled with substantial investments in research and development, fosters innovation in antiepileptic treatments. Moreover, the presence of key market players and the adoption of cutting-edge technologies contribute to the region's leadership in advancing treatment options.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, due to increasing awareness, growing healthcare infrastructure, and a rising incidence of epilepsy-related disorders. A shift towards better diagnostics and increased patient education further fuels the demand for antiepileptic medications in this region. Additionally, with a diverse demographic and a substantial patient base, the region represents a significant growth opportunity for pharmaceutical companies engaged in the development and distribution of antiepileptic drugs.

Key players in the market:

Some of the key players in the Antiepileptic Drugs Market include Eisai Co., Ltd., Novartis AG, Merck KGaA, Teva Pharmaceutical Industries Ltd., AstraZeneca, Abbott, Sanofi, Pfizer Inc., GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Johnson & Johnson Service, Inc., Zogenix, Alkem Labs, SK Biopharmaceuticals and Sun Pharmaceutical Industries Ltd.

Key Developments:

In June 2023, Pfizer announced a strategic collaboration with Truveta to deliver new safety insights on a continuous basis, using verifiable real-world data at scale.

In January 2021, Novartis announced collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

Types of Seizures Covered:

Route of Administrations Covered:

Drug Generations Covered:

Distribution Channels Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global Antiepileptic Drugs Market, By Types of Seizures

6 Global Antiepileptic Drugs Market, By Route of Administration

7 Global Antiepileptic Drugs Market, By Drug Generation

8 Global Antiepileptic Drugs Market, By Distribution Channel

9 Global Antiepileptic Drugs Market, By Geography

10 Key Developments

11 Company Profiling

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â